{"nctId":"NCT01014208","briefTitle":"Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma","startDateStruct":{"date":"2010-03"},"conditions":["Lymphoma, Large-Cell, Diffuse"],"count":447,"armGroups":[{"label":"OFATUMUMAB + DHAP CHEMOTHERAPY REGIMEN","type":"EXPERIMENTAL","interventionNames":["Drug: OFATUMUMAB + DHAP"]},{"label":"RITUXIMAB + DHAP CHEMOTHERAPY REGIMEN","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: RITUXIMAB + DHAP"]}],"interventions":[{"name":"OFATUMUMAB + DHAP","otherNames":[]},{"name":"RITUXIMAB + DHAP","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with CD20 positive DLBCL or grade 3b follicular lymphoma (FL) at original diagnosis.\n* Refractory to, or relapsed following, first-line treatment with rituximab combined with anthracycline- or anthracenedione-based chemotherapy as defined by the protocol.\n* CT with involvement of 2 or more clearly demarcated lesions/ nodes with a long axis \\> 1.5 cm and short axis \\>= 1.0cm or 1 clearly demarcated lesion/ node with a long axis \\> 2.0 cm and short axis \\>= 1.0 cm.\n* Baseline FDG-PET scans must demonstrate positive lesions compatible with CT defined anatomical tumor sites.\n* Age 18 yrs or older.\n* ECOG performance status of 0, 1 or 2.\n* Eligible for high dose chemotherapy and ASCT.\n* Resolution of toxicities from first-line therapy to a grade that in the opinion of the investigator does not contraindicate study participation.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Previous cancer therapy for lymphoma, with the exception of first-line rituximab/ anthracycline- or anthracenedione-based chemotherapy, monotherapy rituximab prior to or combined with first-line chemotherapy, as maintenance therapy, and radiotherapy in a limited field or as a part of the first-line treatment plan.\n* Any anti-cancer therapy, except limited field radiotherapy, within 2 weeks prior to start of study therapy.\n* Planned post-randomization chronic glucocorticoid use (limited acute use is allowed and defined by the protocol) unless administered as therapy for mild COPD or asthma.\n* Clinically significant cardiac disease, active or chronic infections, serious significant diseases, other cancer within last 5 years. History of significant cerebrovascular disease.\n* Prior treatment with anti-CD20 monoclonal antibodies with the exception of rituximab.\n* Abnormal/ inadequate WBC count, liver, and kidney function.\n* Pregnant or lactating women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception during and up to 1 year following dosing completion.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival as Assessed by Independent Reviewers","description":"Progression-free survival is defined as the interval of time from the randomization date until the date of stable disease (SD; failure to attain the criteria needed for a CR or PR and no fulfillment of the criteria for progressive disease \\[PD\\]) after two cycles of salvage chemotherapy, progression, or death, whichever occurs first. Disease progression was based on the assessments of independent reviewers for the disease under study. Disease progression was based on imaging data via the Revised Response Criteria for Malignant Lymphoma (RRCML).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":null},{"groupId":"OG001","value":"1.81","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Overall Response (OR) and Complete Response (CR) After Salvage Chemoimmunotherapy","description":"OR is defined as the number of participants achieving either a complete response (CR) or a partial response (PR). CR is defined as the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. PR is defined as at least a 50% decrease from Baseline in the sum of the product of the diameters of target lesions. RRCML was used to assess CR and PR.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Overall Response (OR) and Complete Response (CR) Three Months After Autologous Stem Cell Transplant","description":"OR is defined as the number of participants achieving either a complete response (CR) or a partial response (PR). CR is defined as the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. PR is defined as at least a 50% decrease from Baseline in the sum of the product of the diameters of target lesions. RRCML was used to assess CR and PR.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival","description":"Event-free survival is defined as the time from randomization to progressive disease (PD; disease whose course is growth, or spread of the disease), stable disease (SD; failure to attain the criteria needed for a CR or PR and no fulfillment of the criteria for PD) after completion of 2 cycles of therapy, commencement of a new treatment for diffuse large B cell lymphoma (DLBCL) (e.g., radiotherapy), or death from any cause, whichever occurs first. Disease progression was based on the assessments of independent reviewers for the disease under study. Disease progression was based on imaging data via the Revised Response Criteria for Malignant Lymphoma (RRCML).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.84","spread":null},{"groupId":"OG001","value":"1.74","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from randomization to death due to any cause. Participants who were still alive by the end of the study were censored.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.17","spread":null},{"groupId":"OG001","value":"13.86","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Ability to Mobilize at Least 2 Million Cluster of Differentiation (CD)34+ Cells Per Kilogram From Peripheral Blood","description":"Stem cell mobilization is the process of stimulating the hematopoietic stem cells (CD34+) to move out of the bone marrow and into the bloodstream, where they can be collected via a process called apheresis. Successful mobilization is defined as the collection of \\>2\\*10\\^6 CD34+ cells/kg. Only those participants, who commenced harvest, following the administration of rituximab or ofatumumab in combination with DHAP combination chemotherapy, were assessed. The number of participants with adequate harvest of CD34+ stem cells (at least 2\\*10\\^6 CD34+ cells/kg) after dosing of salvage therapy in Cycle 2 and Cycle 3 was analyzed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Completing Autologous Stem Cell Transplant (ASCT)","description":"The number of participants who completed ASCT is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) During Treatment","description":"The FACT-G was developed by the Functional Assessment of Chronic Illness Therapy (FACIT) group for use in adults in a wide range of oncology clinical trial populations. The 27 items of the FACT-G are scored in the following domains: Physical Well-being (7 items), Social/Family Wellbeing (7 items), Emotional Well-being (6 items), and Functional Well-being (7 items). Participants responded to the items on a five-point Likert scale ranging from 0, \"Not at all\" to 4, \"Very much.\" The total score ranges from 0 to 108; higher scores indicate a better patient-reported outcome/quality of life. Participants were asked to think back over the past week when responding to the items.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.561","spread":"0.7671"},{"groupId":"OG001","value":"-2.591","spread":"0.7696"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Functional Assessment of Cancer Therapy Lymphoma Trial Outcome Index (FACT-Lym TOI) Total Score During Treatment","description":"The FACT-Lym TOI is a measure that combines the FACT-Lym subscale (15 items; responses to each item range from 0, \"Not at all\" to 4, \"Very much\") with two domains taken from the FACT-G (responses to each item range from \"Not at all \" to \"Very much\"): Physical Well-being (7 items: lack of energy, nausea, meeting family needs, pain, side effects, feels ill, spends time in bed) and Functional Well-being (7 items: ability to work, work fulfilment, ability to enjoy life, illness acceptance, ability to sleep well, enjoying things done for fun, satisfaction with quality of life). This index is designed to be sensitive to changes in treatment regimens. The total FACT-Lym TOI score ranges from 0 to 116; higher scores indicate a better patient-reported outcome/quality of life. Participants were asked to think back over the past week when responding to the items.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.028","spread":"0.9196"},{"groupId":"OG001","value":"-3.156","spread":"0.9204"}]}]}]},{"type":"SECONDARY","title":"Time to Neutrophil and Platelet Recovery After Each Cycle of Salvage Chemotherapy","description":"Neutrophil (absolute neutrophil count \\[ANC\\]) recovery is defined as ANC \\>=0.5\\*10\\^9/Liter and increasing, and platelet (PLT) recovery is defined as PLT \\>=10\\*10\\^9/Liter and increasing. For each cycle, time to ANC recovery is defined as the time from the first dose to the first ANC \\>=0.5\\*10\\^9/Liter and increasing after the nadir in the cycle. For each cycle, time to PLT recovery is defined as the time from the first dose to the first PLT \\>=10\\*10\\^9/L and increasing after the nadir in the cycle.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"12.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"13.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"13.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Engraftment After High-dose Therapy (HDT)/ASCT","description":"Engraftment is defined as 1) three consecutive days when the ANC is ≥0.5x109/L and 2) an unsupported platelet count of ≥20x109/L, and the engraftment date is the date that this occurs. If engraftment was not achieved by Day 42 or the last observation, engraftment was deemed to be a failure, and censoring took place at Day 42 or at the last observation.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":115,"n":223},"commonTop":["Nausea","Anaemia","Thrombocytopenia","Fatigue","Vomiting"]}}}